You're reading the free version. Trader adds the live tape and alerts.
Start tracking
ELVN Sale Disclosure
Collins Helen Louise · SEC Form 4 · Filed Jun 22, 2026
Sale
Calculated transaction value
$114.02K
Collins Helen Louise Chief Medical Officer
ELVN
Enliven Therapeutics
ELVN
Transaction date
Jun 17, 2026
Public filing date
Jun 22, 2026
Filing lag
Filed 5 days later
ELVN daily price context
Close on/before transaction
$44.86
Jun 17, 2026
First close after public filing
$48.6
Jun 23, 2026
30-day return after filing
+8.74%
Through Jul 22, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 2,599 shares @ $43.87
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001701247-26-000010
Filing cohort
Transactions in this filing
Showing 5 of 5
Trades
5
Issuers
1
Estimated value
$231.42K
Buys / sales
0 / 3
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Enliven Therapeutics, Inc. ELVN | Exercise | Jun 17, 2026 | $12.4K |
| Enliven Therapeutics, Inc. ELVN | Sale | Jun 17, 2026 | $54.3K |
| Enliven Therapeutics, Inc. ELVN Current | Sale | Jun 17, 2026 | $114.02K |
| Enliven Therapeutics, Inc. ELVN | Sale | Jun 17, 2026 | $50.69K |
| Enliven Therapeutics, Inc. ELVN | Exercise | Jun 17, 2026 | $0 |